ImmunoCellular Therapeutics, Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2018. For the quarter, the company reported loss before other income was $307,090 against $11,341,867 a year ago. Interest income was $386 against $381 a year ago. Net loss was $306,704 or $0.01 per basic and diluted share against $4,052,070 or $1.14 per basic and diluted share a year ago. The decrease in the net loss is primarily due to the suspension of the ICT-107 phase 3 trial in June of 2017 and reductions in the Company’s other research and development programs along with reductions in general and administrative expenses. For the period, the company reported loss before other income was $1,332,287 against $16,820,765 a year ago. Interest income was $602 against $4,175 a year ago. Net loss was $1,331,685 or $0.03 per basic and diluted share against $9,979,833 or $2.81 per basic and diluted share a year ago. The company reported $3.8 million of cash used in operations during the six months period ended June 30, 2018, compared to $9.5 million in the same period in 2017.